Figure 4.

Immunological responses and clinical efficacy. To evaluate the magnitude of human papillomavirus (HPV)-16 E7–specific Th1 immune response, the numbers of HPV-16 E7–specific interferon-γ–producing cells in peripheral blood were obtained by enzyme-linked immunosorbent spot assay. The spot-forming cell numbers (spot-forming cells per 10^6 peripheral blood monocytes) for each patient were plotted on the y axis. A) Comparisons of spot-forming cells at the study endpoint among regression to normal, regression to cervical intraepithelial neoplasia (CIN) 1, and stable disease (CIN 2-3) groups. B) Change in spot-forming cells for each patient, grouped by treatment type and dose. Red dots depict patients with complete response, and the dotted line represents the median of spot-forming cell change among the full analysis set. ANOVA = analysis of variance; CR = complete response; IFN = interferon.